Efficacy of mibefradil compared with amlodipine in suppressing exercise- induced and daily silent ischemia: Results of a multicenter, placebo- controlled trial

Circulation

Volumn 96, Issue 8, 1997, Pages 2557-2564

  Tzivoni, Dan ^a   Kadr, Honer ^b   Braat, Simon ^f   Rutsch, Wolfgang ^c   Ramires, José Antonio ^d   Kobrin, Isaac ^e  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b OLDCHURCH HOSPITAL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Instituto de Corado   (Brazil)

^e HOFFMANN LA ROCHE INC   (United States)

^f Shaare Zedek Medical Center ^*

Author keywords

Amlodipine; Coronary artery disease; Electrocardiography, ambulatory; Exercise; Ischemia; Mibefradil

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; MIBEFRADIL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; HEART MUSCLE ISCHEMIA; HUMAN; INOTROPISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

EID: 0030761387     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.8.2557     Document Type: Article

References (37)

1. Stern S, Tzivoni D. Early detection of silent ischemic heart disease by 24-hour electrocardiographic monitoring of active subjects. Br Heart J. 1974;39:481-486.
2. Schang SJ, Pepine CJ. Transient asymptomatic ST segment depression during daily activity. Am J Cardiol. 1977;39:396-402.
3. Tzivoni D, Gavish A, Benhorin J, Keren A, Stern S. Myocardial ischemia during daily activities and stress. Am J Cardiol. 1986;58: 47b-50b.
4. Tzivoni D, Gavish A, Zin D, Gottlieb S, Moriel M, Keren A, Banai S, Stern S. Prognostic significance of ischemic episodes in patients with previous myocardial infarction. Am J Cardiol. 1988;62:661-664.
5. Rocco MB, Nabel EG, Campbell S, Goldman M, Barry J, Mead K, Selwyn AP. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with stable coronary artery disease. Circulation. 1988;78:877-884.
6. Tzivoni D, Weisz G, Gavish A, Zin D, Keren A, Stern S. Comparison of mortality and myocardial infarction rates in stable angina pectoris with and without ischemic episodes during daily activities. Am J Cardiol. 1989;63:272-273.
7. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation. 1990;81:748-756.
8. Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. 1986;314:1214-1219.
9. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, Miller E. Marks RG, Thadani U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia STudy (ASIST). Circulation. 1994;90:762-768.
10. Lim R, Dyke L, Dymond DS. Effect on prognosis of abolition of exercise-induced painless myocardial ischemia by medical therapy. Am J Cardiol. 1992;69:733-739.
11. Subramaniam V, Bowles MJ, Khurmi HS, Davies AB, Raftery EB. Rationale for the choice of calcium antagonists in chronic stable angina: an objective double-blind placebo-controlled comparison of nifedipine and verapamil. Am J Cardiol. 1982;50:1173-1179.
12. Frishman W, Charlap S, Kimmel B. Effects of diltiazem, nifedipine, and their combination in transient ST-segment deviations on the ambulatory ECG in patients with stable angina pectoris. Circulation. 1988;77:774-786.
13. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol. 1989;14:713-721.
14. 2+ channel in cardiac tissue. Eur J Pharmacol. 1995;290: 155-158.
15. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
16. Clozel JP, Osterrieder W, Kleinbloesem C, Welker HA, Schläppi B, Tudor R, Hefti F, Schmitt R, Eggers H. Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev. 1991; 9:4-17.
17. Schmitt R, Kleinbloesem C, Belz G, Schroeter V, Feifes U, Pazenel H, Kirch W, Halabi A, Woittiez A, Welker J, van Brummelen P. Hemodynamic and humoral effect of the novel calcium antagonist Ro-5967 in patients with hypertension. Clin Pharmacol Ther. 1992; 52:314-323.
18. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther. 1990;4:731-736.
19. Bernink PJLM, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967). Hypertension. 1996;27:426-432.
20. Bakx AL, van der Wall EE, Braun S, Emanuelsson H, Bruschke AV, Kobrin I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J. 1995; 130:748-757.
21. Braun S, van der Wall EE, Emanuelsson H, Kobrin I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol. 1996;27:317-333.
22. Rosseau MG, Harashida W, van Eyll C, Hess OM, Benedict CR, Ahn S, Chapelle F, Kobrin I, Pouleur H. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol.. 1996;28:972-979.
23. Welker HA, Eggers H, Kleinbloesem C, Erb K, Breithaupt K, Butzer R, Belz GG. Ro 40-5967, pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol. 1989;36(suppl A):A304.
24. Agresti Alan. Categorical Data Analysis. New York, NY: John Wiley & Sons; 1994: chap 6.
25. Taylor SH. The efficacy of amlodipine in myocardial ischemia. Am Heart J. 1989;118:1123-1126.
26. Deanfield JE, Detry JRG, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE trial). J Am Coll Cardiol. 1994;24:1460-1467.
27. Davies RF, Habibi H, Klinke WP, Dessain P, Nadeau C. Phaneuf DC, Lepage S. Raman S, Hebert M, Foris K, Linden W, Buttars JA. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol. 1995;25:619-625.
28. Kawanishi T, Reid C, Morrison B, Rahimtoola S. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992:19:409-417.
29. Siu SC, Jacoby RM, Phillips RT, Nesto RN. Comparative efficacy of nifedipine, gastrointestinal therapeutic system versus diltiazem when added to beta-blockers in stable angina pectoris. Am J Cardiol. 1993;71:887-892.
30. Theroux P, Baird M, Juneau M, Warnica W, Klinke P, Kostuk W, Pflugfelder P, Lavallee E, Chin C, Dempsey E, Grace M, Lalonde Y, Waters D. Effect of diltiazem on symptomatic and asymptomatic episodes of ST-segment depression occurring during daily life and during exercise. Circulation. 1991;84:15-22.
31. Stone PH, Gibson RS. Glasser SP, DeWood MA, Parker JD, Kawanishi DT, Crawford MH, Messineo FC, Shook TL, Raby K, Curtis DG, Hoop RS, Young PM, Braunwald E. Comparison of propanolol, diltiazem and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance and anginal symptoms (the ASIS study). Circulation. 1990;82:1962-1972.
32. Hill JA. Gonzalez JI, Kolb R, Pepine CJ. Effects of atenolol alone, nifedipine alone and their combination on ambulant myocardial ischemia. Am J Cardiol. 1991;67:671-675.
33. Von Arnim T. Medical treatment to reduce total ischemic burden: Total Ischemic Burden Bisoprolol Study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine - the TIBBS Investigators. J Am Coll Cardiol. 1995;25:231-238.
34. Borzak S, Fenton T, Glasser SP, Shook TL, MacCallum G, Young PM, Stone PH, for the Angina and Silent Ischemia Study Group (ASIS group). Discordance between effects of anti-ischemic therapy on ambulatory ischemia, exercise performance, and anginal symptoms in patients with stable angina pectoris. J Am Coll Cardiol. 1993;32:1605-1611.
35. Benhorin J, Model M, Gavish A, Medina A, Banai S, Shapira M, Stern S, Tzivoni D. Usefulness of severity of myocardial ischemia on exercise testing in predicting the severity of myocardial ischemia during daily activities. Am J Cardiol. 1991;168:176-180.
36. Mody FV, Nademanee K, Intarachot V, Josephson MA, Robertson HA, Singh BN. Severity of silent ischemia on ambulatory ECG monitoring in patients with stable angina pectoris: relation to prognostic determinants during exercise stress testing and coronary angiography. J Am Coll Cardiol. 1994;74:991-996.
37. Stone PH, Chaitman BR, McMahon RP, Andrews TC, MacCallum G, Sharaf B, Frishman W. Deanfield JE, Sopko G, Pratt C, Goldberg AD, Rogers WJ, Hill J, Proschan M. Pepine CJ, Bourassa MG, Conti RC, for the ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease. Circulation. 1996;94:1537-1544.